近日，一则‘不同品牌奥司他韦售价相差70倍’的消息引发公众关注。奥司他韦（Oseltamivir）是一种广泛用于治疗和预防流感的抗病毒药物，尤其在流感高发季节需求激增。然而，市场上同一成分、相同剂型的奥司他韦，价格却从几元到数百元不等，最大价差竟达70倍。造成价格差异的主要原因包括：是否为原研药或仿制药、品牌溢价、销售渠道（如医院、药店、电商平台）、包装规格以及是否纳入医保目录等。原研药‘达菲’由罗氏公司研发，因专利保护期结束，国内多家药企已推出仿制药，成本大幅降低，售价自然更亲民。此外，部分高价产品可能包含附加服务、特殊剂型（如颗粒剂更适合儿童）或营销成本。专家提醒，只要是国家药监局批准的正规药品，无论原研还是仿制，在有效性和安全性上均需通过一致性评价，疗效相当。消费者在选购时应理性看待品牌与价格，优先选择正规渠道、查看批准文号，并遵医嘱使用，避免盲目追求高价或低价产品。
Recently, news that ‘prices of oseltamivir from different brands vary by as much as 70-fold’ has drawn public attention. Oseltamivir is a widely used antiviral medication for treating and preventing influenza, especially in high flu seasons when demand surges. However, products containing the same active ingredient and dosage form are priced anywhere from a few yuan to several hundred yuan—creating a staggering 70x price gap.Key factors behind this disparity include whether the product is an originator (brand-name) drug or a generic, brand premium, sales channels (hospitals, pharmacies, e-commerce platforms), packaging size, and inclusion in China’s national health insurance reimbursement list. The original drug, Tamiflu, developed by Roche, lost patent protection years ago, enabling numerous Chinese manufacturers to produce affordable generics with significantly lower costs.Experts emphasize that all officially approved oseltamivir products—whether originator or generic—must pass bioequivalence evaluations mandated by China’s National Medical Products Administration, ensuring comparable efficacy and safety. Consumers are advised to purchase from reputable sources, check official approval numbers, and follow medical guidance rather than choosing solely based on price or brand reputation.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/2947.html